ERT Appoints New Vice President of Project Management
23 July 2009 - 12:00AM
PR Newswire (US)
PHILADELPHIA, July 22 /PRNewswire-FirstCall/ -- ERT (NASDAQ:ERES),
a leading provider of centralized ECG and eClinical technology,
ePRO, and other services to the biopharmaceutical, medical device,
and related industries, announced the appointment of a new Vice
President of Project Management, Tammy Miller. Ms. Miller will
report to the Executive Vice President of Cardiac Safety
Operations. In this new role, Ms. Miller will be responsible for
the global implementation and delivery of ERT's Project Assurance
methodology, including developing and executing strategic plans to
maximize customer service excellence. Ms. Miller has 24 years'
experience of working in the health care industry, with 12 years in
the CRO and pharmaceutical industry. She has an MBA in Global
Management from the University of Phoenix and has built up
extensive project management experience, including scenario
building, forecasting, budgeting resource allocation, and timeline
management. Ms. Miller joins ERT from Quintiles Inc where she
worked as Group Director for CNS. ERT's unique Project Assurance
methodology is an SOP-driven approach that proactively addresses
the full range of support functions required to ensure the success
of a clinical study. The ERT focus on project management and
operational excellence ensures global consistency, reliable data
collection, and customer satisfaction. The global Project
Management team works closely with the Cardiac Safety and Customer
Care teams. Amy Furlong, EVP, Cardiac Safety Operations at ERT,
said, "With Tammy's extensive experience in the industry, we are
confident she will be a key member of our senior management team.
Our decision to appoint Tammy as Vice President, Project
Management, demonstrates our continued commitment to delivering
operational excellence to our customers." Amy added, "In recent
years, the Company has grown significantly in terms of scale and
reputation, and with this appointment, we plan to continue to grow
from strength to strength. We are delighted to welcome Tammy to the
ERT team." ERT is a leading provider of technology and services to
the biopharmaceutical and medical device industries around the
world. The key areas of ERT products and services - ERT Cardiac
Safety Solutions, ERT ePRO Solutions, and ERT Clinical Research
Consulting Group - are all enabled by the Company's innovative
technology platform - EXPERT(TM). EXPERT is a robust, secure, and
validated clinical research workflow-processing system that powers
centralized electronic data collection, data management, and
information exchange. For further information on ERT and its
technology and services, please email , call +1 215 972 0420 or
visit http://www.ert.com/. For further press information, please
contact Fiona Robinson, The Scott Partnership, 1 Whiteside, Station
Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44
1477 539539, Fax +44 1477 539540, Email About ERT Based in
Philadelphia, PA, ERT (eResearchTechnology, Inc.) (www.ert.com) is
a provider of technology and services to the global
biopharmaceutical and medical device industries. The Company is the
market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The Company also provides
technology and services to streamline the clinical trials process
by enabling its customers to automate the collection, analysis and
distribution of clinical data in all phases of clinical
development. Statements included in this release may constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements,
including, but not limited to, 2009 financial guidance, involve a
number of risks and uncertainties such as the Company's ability to
obtain new contracts and accurately estimate net revenues due to
uncertain regulatory guidance, variability in size, scope and
duration of projects, and internal issues at the sponsoring client,
integration of acquisitions, competitive factors, technological
development, and market demand. As a result, actual results may
differ materially from any financial outlooks stated herein.
Further information on potential factors that could affect the
Company's financial results can be found in the Company's Reports
on Form 10-K and 10-Q filed with the Securities and Exchange
Commission. The Company undertakes no obligation to publicly update
any forward-looking statement, whether as a result of new
information, future events, or otherwise. DATASOURCE: ERT CONTACT:
Fiona Robinson of The Scott Partnership, +44-1477-539539, ; or John
Blakeley of ERT, +1-215-972-0420, Web Site: http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024